title: [Cutaneopulmonary sarcoidosis during pegylated interferon plus ribavirin therapy].
authors.forename: J J
authors.initials: JJ
authors.lastname: Sánchez-Ruano
authors.forename: T
authors.initials: T
authors.lastname: Artaza-Varasa
authors.forename: R
authors.initials: R
authors.lastname: Gómez-Rodríguez
authors.forename: C
authors.initials: C
authors.lastname: González de Frutos
authors.forename: A
authors.initials: A
authors.lastname: Repiso-Ortega
authors.forename: M
authors.initials: M
authors.lastname: Alcántara-Torres
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D012507:Sarcoidosis / Q000139:chemically induced*; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a